Albuminuria by diabetes mellitus: Marker and motor of diabetic nephropathy and vascular complications

被引:0
作者
Hunger-Dathe W. [1 ,2 ]
Wolf G. [1 ]
机构
[1] Klinik für Innere Medizin III, Klinikum, Friedrich-Schiller-Universität, Jena
[2] Klinik für Innere Medizin III, Klinikum, Friedrich-Schiller-Universität
来源
Der Diabetologe | 2006年 / 2卷 / 5期
关键词
Cardiovascular morbidity; Diabetic nephropathy; Microalbuminuria; Myocardial infarct; Stroke;
D O I
10.1007/s11428-006-0069-z
中图分类号
学科分类号
摘要
Diabetic nephropathy requires intensive treatment as it is the main reason for the morbidity and mortality resulting from diabetes mellitus. Patients with diabetic nephropathy have a significantly higher mortality rate due to cardiovascular events such as myocardial infarct or stroke. Microalbuminuria is the earliest clinical sign of diabetic renal disease and is also a marker for increased cardiovascular morbidity and mortality. Thus, its early detection allows not only for effective secondary prevention of the progression of diabetic nephropathy, but is also an indication for the implementation of an individually-tailored cardiovascular risk reduction management program. People with diabetes mellitus are high risk patients who need intensive monitoring and intensive supportive therapy. © Springer Medizin Verlag 2006.
引用
收藏
页码:400 / 409
页数:9
相关论文
共 33 条
[1]  
Al-Futaisi A., Al-Zakwani I., Almahrezi A., Et al., Prevalence and predictors of microalbuminuria in patients with type 2 diabetes mellitus: A cross-sectional observational study in Oman, Diabetes Res Clin Pract, 72, pp. 212-215, (2005)
[2]  
Bakris G.L., Fonseca V., Katholi R.E., Et al., Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes, Hypertension, 46, pp. 1309-1315, (2005)
[3]  
Barnett A.H., Bain S.C., Bouter P., Et al., Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy, N Engl J Med, 351, pp. 1952-1961, (2004)
[4]  
Bohlender J.M., Franke S., Stein G., Wolf G., Advanced glycation end products and the kidney, Am J Physiol Renal Physiol, 289, pp. 645-659, (2005)
[5]  
Cao J.J., Barzilay J.I., Peterson D., Et al., The association of microalbuminuria with clinical cardiovascular disease and subclinical atherosclerosis in the elderly: The cardiovascular health study, Atherosclerosis, (2005)
[6]  
Cederholm J., Eliasson B., Nilsson P.M., Et al., Microalbuminuria and riskfactors in type 1 and type 2 diabetic patients, Diabetes Res Clin Pract, 67, pp. 258-266, (2005)
[7]  
Gaede P., Vedel P., Larsen N., Et al., Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes, N Engl J Med, 348, pp. 383-393, (2003)
[8]  
Gerstein H.C., Mann J.F., Yi Q., Et al., Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals, JAMA, 286, pp. 421-426, (2001)
[9]  
Hillege H.L., Fidler V., Diercks G.F., Et al., Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population, Circulation, 106, pp. 1777-1782, (2002)
[10]  
Kramer H., Molitch M.E., Screening for kidney disease in adults with diabetes, Diabetes Care, 28, pp. 1813-1816, (2005)